Business Wire

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Share

Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023. The new candidate, Miki Tsusaka, will join the board effective June 28th, if approved by the shareholders. Furthermore, Masato Iwasaki, Representative Director, Japan General Affairs expressed his intention to retire on the same day. All other current board members who are not our Audit & Supervisory Committee members will be proposed for re-election.

“On behalf of Takeda’s Board of Directors, I would like to thank Masato Iwasaki for his invaluable contribution to Takeda. In his nearly 40-year career with Takeda, he has made a significant impact supporting Takeda transformation to become a global biopharmaceutical company, while staying true to our values.” said Christophe Weber, Representative Director, President and Chief Executive Officer of Takeda.

Dr. Iwasaki started his career at Takeda in 1985, in sales and marketing in Japan. He was later appointed as Head of the Strategic Product Planning Department in 2008 and then became Head of Pharmaceutical Marketing Division as well as Director in 2012. He served as President of the Japan Pharma Business Unit, a member of the Takeda Executive Team, from 2014, and assumed Japan General Affairs in 2021 to oversee overall business activities in Japan. Milano Furuta, who is currently President of Japan Pharma Business Unit will be named Japan Country Head in addition to his current role.

Miki Tsusaka is current President of Microsoft Japan, appointed in February 2023. Prior to this role, Ms. Tsusaka was a Senior Partner and Managing Director at Boston Consulting Group (BCG), where she helped various industries with growth strategies, profitability, and digital transformation. At BCG, she established strategic consulting groups, specializing in marketing, sales and pricing strategy development, served as Chief Marketing Officer (CMO) and was a member of the Executive Committee for two three-year terms. Ms. Tsusaka holds a Bachelor of Arts in Government and East Asian Studies from Harvard University and an MBA from the Harvard Business School.

Masami Iijima, Chairperson of the Nomination Committee commented “Takeda is highly committed to advancing the diversity of the Board, including gender, nationalities, skills and experiences, while ensuring balanced representation of our global stakeholders. With Miki Tsusaka joining our Board, we will be able to strengthen further our governance.”

“We are very excited tohave Miki Tsusaka joining our board. With her deep expertise and experience, we look forward to further pursuing our vision tobecome a leading digital biopharmaceutical company focusing on delivering life-transforming treatments.” commented Christophe Weber.

Ms. Tsusaka commented “I am honored to be a candidate to join Takeda’s Board of Directors. With my deep respect for Takeda’s strong leadership in biopharmaceutical science, values-based culture and sustainability, I look forward to working alongside the rest of the Board to help deliver on Takeda’s purpose and vision.”

Candidates for Directors Who are Not Audit and Supervisory Committee Members

Name

Category

Expected Role

Christophe Weber

Internal

Existing

Representative Director,
President & Chief Executive Officer

Andrew Plump

Internal

Existing

Director, President, Research & Development

Constantine Saroukos

Internal

Existing

Director, Chief Financial Officer

Masami Iijima

External

Existing

External Director, Chair of the Board Meeting

Olivier Bohuon

External

Existing

External Director

Jean-Luc Butel

External

Existing

External Director

Ian Clark

External

Existing

External Director

Steven Gillis

External

Existing

External Director

John Maraganore

External

Existing

External Director

Michel Orsinger

External

Existing

External Director

Miki Tsusaka

External

New

External Director

The following four Directors who are Audit and Supervisory Committee members were elected at the 146th Ordinary General Meeting of Shareholders held in 2022 and their terms of office will continue until the 148th Ordinary General Meeting of Shareholders held in 2024.

Name

Category

Expected Role

Koji Hatsukawa

External

Existing

External Director, Head of Audit and Supervisory Committee

Yoshiaki Fujimori

External

Existing

External Director, Audit and Supervisory Committee Member

Emiko Higashi

External

Existing

External Director, Audit and Supervisory Committee Member

Kimberly A. Reed

External

Existing

External Director, Audit and Supervisory Committee Member

[Note: The members of the Nomination Committee and Compensation Committee will be discussed and determined at the Board of Directors meeting to be held after the 147th Ordinary General Meeting of Shareholders.]

About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Japanese Media
Jun Saito
jun.saito@takeda.com
+81 (0) 3-3278-3414

U.S. and International Media
Megan Ostrower
megan.ostrower@takeda.com
+1 772-559-4924

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye